/

Empresas

Ne

No verificado

NextPoint Therapeutics

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosOncología

5 Comunicados de prensa

Ver todos los comunicados de prensa

09/02/2026

Industria

Ciencia

Biotecnología

Farmacéutica

Oncología

Sanidad

Salud

Medicina - Varios

NextPoint Therapeutics Announces Clinical Entry of NPX372, a First-in-Class B7-H7–Targeted T Cell Engager to Treat Solid Tumors

Fuente

NextPoint Therapeutics

Editor

1.00

0

25/04/2025

Eventos

Industria

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

NextPoint Therapeutics to Showcase Pioneering Preclinical Data on NPX125, a Novel B7-H7 Targeted Antibody-Drug Conjugate (ADC) at AACR Annual Meeting 2025

Fuente

NextPoint Therapeutics

Editor

1.00

0

07/04/2025

Eventos

Industria

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

NextPoint Therapeutics to Highlight Antibody-Drug Conjugate (ADC) and T Cell Engager (TCE) Preclinical Findings Targeting Novel B7-H7 Pathway at AACR Annual Meeting

Fuente

NextPoint Therapeutics

Editor

1.00

0

07/11/2024

Eventos

Industria

Ciencia

Biotecnología

Farmacéutica

Oncología

Salud

VIH, SIDA y enfermedades autoinmunes

Medicina - Varios

NextPoint Therapeutics Announces Upcoming Poster Presentation on a B7-H7 Directed T Cell Engager Therapy at SITC2024

Fuente

NextPoint Therapeutics

Editor

1.00

0

05/09/2024

Industria

Biotecnología

Farmacéutica

Salud

Oncología

NextPoint Therapeutics Announces First-in-class T Cell Engager NPX372 As New Drug Candidate Targeting B7-H7 in Solid Tumors

Fuente

NextPoint Therapeutics

Editor

1.00

0

Seguidores

0

Compatibilidad

0